Obliterating Airway Bronchus Sign of Occult Malignancy in Sarcoid Conglomerate Fibrotic Masses

Niall McVeigh¹, David J. Murphy²,4, Edward McKone³,4, Jonathan D. Dodd²,4
Departments of ¹Cardiothoracic Surgery, ²Radiology, ³Respiratory Medicine, St. Vincent’s University College, Dublin, Ireland, ⁴School of Medicine, University College Dublin, Dublin 4, Ireland.

INTRODUCTION

A 62-year-old male presented to the emergency department with increasing fatigue and breathlessness over a week. He suffered from chronic fibrotic pulmonary sarcoid and emphysema for 11 years. He was an ex-smoker having stopped when diagnosed with sarcoidosis. Examination revealed extensive wheeze with reduced air entry bilaterally. His spirometry yielded a FEV₁ of 1.21 L (32% predicted), FVC 4.85 L (99% predicted), and a diffusing capacity of the lungs for carbon monoxide of 3.24 mmol/(min*kPa) (30% predicted).

Serial chest computed tomography (CT) scans over 10 years showed an interval increase in fibrotic changes in the upper and middle lung zones and perihilar conglomerate fibrotic masses (CFMs) in a typical distribution and appearance for Stage IV chronic fibrotic sarcoid [Figures 1a and b]. Clinically, he reported no change in his baseline dyspnea between 2014 and 2016. Imaging appearances remained stable until 2019 when a repeat chest CT showed an increase in size of the CFMs [Figure 1c]. A PET-CT scan was acquired to assess lung and nodal disease activity because of his worsening dyspnea. It showed no nodal uptake but increased uptake in the right perihilar CFM [Figure 1d]. Subsequent percutaneous CT-guided biopsy revealed squamous cell carcinoma of the lung. Retrospective review of his serial chest CT scans showed obliteration of the airway bronchi within the conglomerate fibrotic mass, caused by the underlying lung carcinoma. He was surgically inoperable due to his severe underlying lung disease and was treated with chemotherapy.

DISCUSSION

CFMs are common in fibrotic sarcoid, occurring in 17–20% of cases.[1] They typically show progression in size overtime, making it challenging for radiologists to detect occult malignancy.
Within CFMs, patients with sarcoid have a slightly higher incidence of solid organ malignancy and immune-related malignancy, with an increased risk of lung malignancy typically presenting during the first 5 years of disease. This is followed by a progressive decrease in risk to 10 years when lung malignancy risk is significantly lower than expected in the general population. As the incidence of concurrent lung malignancy in sarcoidosis is a rare entity, it is often subject to misdiagnosis resulting in a delay in appropriate patient treatment.

Many potential causes for obliterating airways can be seen in the lungs, including mucus plugs, aspiration, and pneumonia. Typically, the airways within CFMs are stretched apart by the traction from the surrounding fibrotic process and become dilated, making them easier to detect. Conversely, in malignancy, there is often occlusion or partial occlusion of the airways. The progressively increasing size of benign CFMs on serial CT imaging makes differentiating benign from malignant disease particularly difficult. A further issue is that serial surveillance high-resolution chest CT imaging in sarcoid is typically performed without intravenous contrast, making occult malignancy even harder to detect. We propose that evaluation of CFMs should include an assessment of the airways within these lesions, and an obliterating bronchus should raise the suspicion of an occult malignancy.

**CONCLUSION**

Imaging interpretation of CFMs should include an assessment of the airways within the masses. The obliterating bronchus sign in CFMs on chest CT should alert the radiologist to the possible diagnosis of an occult lung malignancy.

**Declaration of patient consent**

Patient’s consent not required as patients’ identity is not disclosed or compromised.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Akira M, Kozuka T, Inoue Y, Sakatani M. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest 2005;127:185-91.
2. Sogaard KK, Sværke C, Thomsen RW, Nørgaard M. Sarcoidosis and subsequent cancer risk: A Danish nationwide cohort study. Eur Respir J 2015;45:269-72.
3. Bonifazi M, Bravi F, Gasparini S, La Vecchia C, Gabrielli A, Wells AU, et al. Sarcoidosis and cancer risk: Systematic review and meta-analysis of observational studies. Chest 2015;147:778-91.
4. Shin HJ, Kim MS, Kho BG, Park HY, Kim TO, Park CK, et al. Delayed diagnosis of lung cancer due to misdiagnosis as worsening of sarcoidosis: A case report. BMC Pulm Med 2020;20:71.
5. Yamawaki H, Ishii Y, Kitamura S. Concurrence of sarcoidosis and lung cancer. A report of four cases. Respiration 2000;67:90-3.

How to cite this article: McVeigh N, Murphy DJ, McKone E, Dodd JD. Obliterating airway bronchus sign of occult malignancy in sarcoid conglomerate fibrotic masses. J Clin Imaging Sci 2021;11:12.